Hoya Vision Care hosted a myopia symposium recently at the International Myopia Conference (IMC), with researchers sharing their latest findings of the clinical application of the Miyosmart spectacle lens and its role in myopia management.
Under the theme ‘The Latest Insights to Advance Myopia Management’ new European data were shared on emmetropic eye growth, combination treatment, as well as relative peripheral refraction (RPR). Dr Andrea Lembo of the University Hospital San Giuseppe Multimedica in Milan presented results of one-year clinical application of the Miyosmart lens in combination with 0.01% atropine drops in myopic European children and adolescents. Axial elongation and myopia progression were reduced, with the combination treatment achieving maximum effect, he said.
Professor Hakan Kaymak of the Internationale Innovative Ophthalmochirurgie in Duesseldorf presented the findings of his study on axial length growth with Miyosmart lenses. The data and previous clinical study results showed that German children adapt very well to Miyosmart spectacle lenses with no safety concerns, even in combination with low-dose atropine.
Professor Carly Lam of The Hong Kong Polytechnic University then discussed how Miyosmart’s myopia control effect was stronger in children with baseline hyperopic RPR than in children with baseline myopic RPR.
“We are very pleased to be able to share the latest evidence-based approach to myopia management at IMC 2022,” said May Zhang, Hoya Vision Care’s global head of professional affairs. “Hoya Vision Care continues to be a leader in addressing myopia in children and championing new practices like the successful combination treatment of the Miyosmart spectacle lens and atropine drops, as well as continued support of clinical studies in multiple countries to help eyecare professionals make informed decisions.”
